Evonile Pharma: Completes Minipress Minipres Acquisition for ₹1,250 Crore

• Evonile Pharma Limited acquired the Minipress and Minipres brands from Pfizer in India.
• The acquisition was valued at approximately 1,250 crores.
• The transaction signed and closed on September 7, 2026.
• Shardul Amarchand Mangaldas & Co advised Evonile Pharma on all aspects of the deal.
• Partners Karun Prakash and Anant Dang led the advisory team for Shardul Amarchand Mangaldas & Co.

Lawyers advising pharmaceutical clients on M&A in India should closely examine this transaction as a benchmark for similar brand divestitures and acquisitions.

Evonile Pharma Limited has successfully completed a significant acquisition in the Indian pharmaceutical market, securing the well-known Minipress and Minipres brands from Pfizer. This strategic Evonile Pharma Minipress Minipres acquisition was finalized for an approximate consideration of 1,250 crores. The transaction, which involved a major Pfizer India brand sale, reached its signing and closing stages concurrently on September 7, 2026, marking a swift and decisive transfer of ownership for these established product lines.

This move by Evonile Pharma underscores a growing trend of companies bolstering their portfolios with established product lines, particularly those with a strong market presence and recognized efficacy. The acquisition of both Minipress and Minipres represents a notable expansion for Evonile Pharma within the competitive Indian healthcare landscape, adding key assets to its therapeutic offerings and potentially strengthening its market position in relevant segments.

The complex legal aspects of this substantial brand acquisition were expertly navigated by Shardul Amarchand Mangaldas & Co (SAM), which provided comprehensive advisory services to Evonile Pharma Limited. SAM's involvement spanned all facets of the transaction, ensuring a smooth and efficient process for the Evonile Pharma Minipress Minipres acquisition, from due diligence to the final closing.

The legal team spearheading this significant Shardul Amarchand Mangaldas Evonile deal was led by Partners Karun Prakash and Anant Dang. They were supported by a large and experienced team, including Partners Veena Sivaramakrishnan, J.V. Abhay, Rohan Arora, and Mohit Bhatia. Further contributions came from Counsel Devaditya Chakravarti, Principal Associates Tanay Khanna, Leoni Mahanta, Rahul Shukla, and Yash Kahandole, Senior Associate Nishal Makharia, and Associates Aagam Jain, Shivani Pattnaik, Arushi Tiwari, Dhruv Bhartia, Anshika Chadha, and Anushka Gupta, highlighting the extensive legal expertise deployed for the successful Karun Prakash Anant Dang transaction.

This particular Minipress Minipres brand acquisition holds considerable importance for the broader landscape of pharmaceutical M&A in India. The substantial valuation of approximately 1,250 crores for established brands like Minipress and Minipres sets a notable precedent for future deal structures and pricing expectations within the sector. It signals continued robust activity in the Indian pharmaceutical market, especially for well-recognized product lines that offer immediate revenue streams and market penetration.

Lawyers advising pharmaceutical clients on M&A in India should closely examine this transaction as a benchmark for similar brand divestitures and acquisitions. The successful execution of this Evonile Pharma Minipress Minipres acquisition, particularly the simultaneous signing and closing on September 7, 2026, offers valuable insights into efficient deal-making processes for established assets. It reinforces the attractiveness of the Indian market for strategic acquisitions aimed at consolidating or expanding market share through proven brands, demonstrating a clear appetite for high-value pharmaceutical assets. This Pfizer India brand sale exemplifies the strategic value placed on legacy brands in a dynamic healthcare environment, providing a blueprint for future transactions.

Lawyers advising pharmaceutical clients on M&A in India should note this significant brand acquisition as a precedent for deal structures and valuations in the sector, particularly concerning established product lines.

Source: Original reporting via legal firm announcement